Indiana to receive nearly $793K in Amgen settlement

Back to TopCommentsE-mailPrintBookmark and Share

Amgen Inc. has agreed to pay Indiana nearly $793,000 as part of a larger settlement to resolve allegations it paid kickbacks to physicians who prescribed some of its drugs for unapproved uses.

The Indiana attorney general's office says the deal is part of a $612 million civil settlement with the federal government and six states, including Indiana.

The Thousand Oaks, Calif., company pleaded guilty Tuesday in federal court in New York to illegally introducing a misbranded drug into interstate commerce. As part of the criminal case, the company will pay a $136 million fine and a $14 million forfeiture.

The deal settles 10 lawsuits filed around the country.

Officials say Amgen illegally marketed five of its prescription drugs, including the anemia drug Aranesp, and submitted inaccurate price data to Medicaid.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ